| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 2 | 2,000 | ₹2,78,000 |
| HNI / NII | 3 | 3,000 | ₹4,17,000 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | 15.94× | 36,000 | 5,74,000 | ₹0.50 Cr |
| NII / HNI (Total) | 1.30× | 17,55,000 | 22,86,000 | ₹24.39 Cr |
| Retail Investors | 2.92× | 17,92,000 | 52,28,000 | ₹24.91 Cr |
| Total ** | 2.26× | 35,83,000 | 80,88,000 | ₹49.80 Cr |
| Market Maker * | 1× | 1,89,000 | 1,89,000 | ₹2.63 |
| Metric | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 28.63 | 38.33 | 15.34 |
| PAT | 8.66 | 9.79 | 2.50 |
| EBITDA | 13.45 | 15.21 | 5.63 |
| Net Worth | 17.12 | 14.73 | 4.94 |
| Total Assets | 65.17 | 39.12 | 19.53 |
| Reserves | 7.94 | 5.55 | 4.84 |
| Borrowings | 38.17 | 15.01 | 10.49 |
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare.
Product portfolio:
It offers comprehensive range of products, including generic drugs, branded pharmaceuticals, over the counter (OTC) products, and other medications.
The company operates on a B2B model, focusing exclusively on contract manufacturing. It develop formulations for various companies in accordance with their specific requirements and product specifications. It is certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh.
It has two manufacturing facilities in Indore, Madhya Pradesh.
Competitive Strengths